About
Delphi Diagnostics is focused on helping patients, providers and the healthcare system by providing next generation diagnostic tests to optimize breast cancer treatment decisions.
Our History
Founded in 2016, Delphi Diagnostics holds an exclusive license from MD Anderson for current & future innovations by Dr. Fraser Symmans. Our operational foundation has been established and we are poised to bring the valuable information from the EAI test to more patients and providers as our company expands.
Our Mission
Our mission at Delphi Diagnostics is to help patients, clinicians, and healthcare systems by maximizing disease-free breast cancer survival, while minimizing toxicity and avoiding non-beneficial treatments.
Contact Us
Want to learn more about the Endocrine Activity Index (EAI) or Delphi Diagnostics?